Abstract: Provided herein are methods and kits for labeling endonuclease-treated cells. The methods comprise: contacting the cells to be labelled with at least one endonuclease suitable for targeting a genomic region of interest, and first and second nucleic acids suitable for introducing one or more silent (or optionally non-silent) mutation(s) in the genomic region by homology-directed repair (HDR). The mutation(s) introduced by the first nucleic acid differ from the mutation(s) introduced by the second nucleic acid.

Abstract: This invention relates to an agent that modulates the activity of a micro ribonucleic acid (miRNA), said miRNA being selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-5p and miRNA 542-5p, for use in the treatment of HER2-dependent cancer.

Abstract: A method for diagnosing or prognosing, multiple sclerosis including the steps of (a) measuring the amount of at least one first protein as set forth in SEQ ID NO: 1, the at least first protein belonging to the group of proteins: a first protein, a second protein, a third protein, a fourth protein and a fifth protein, as set forth in SEQ ID NO 1 to 5, (b) comparing the amount of the at least first protein with the amount of the same protein in a control sample, and (c) determining the status of the biological sample.

Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

Abstract: Disclosed are CD31shed agonists for use in the prevention and/or treatment of reperfusion injury. These CD31shed agonists are peptides or peptidomimetics thereof that are able to restore CD31 signaling in cells bearing a truncated form of CD31 called CD31shed. The CD31shed agonists particularly protect from organ damages caused by reperfusion used to treat ischemia.

Abstract: The present invention relates to methods to identify substances which affect bacterial cell division by interfering with the function of LOP1, comprising bringing into contact a purified protein selected from the group: FtsZ, FtsQ, FtsL, FtsI and FtsN; with purified LOP1 protein and then assaying the formation of complexes between LOP1 and the selected purified protein in the presence and absence of a substance to be tested and then selecting substances from step b) which affect the formation of complexes when present. The present invention also relates to inhibitors of the activity and expression of LOP 1.

Abstract: Bioprinting station (1) comprising:—a Bioprinting device (4) adapted to deposit a pattern of biological material (2) onto an area of interest (3a) of a substrate (3),—an imaging system (15) adapted to acquire an image of the substrate (3) and to reveal on the acquired image the area of interest (3a) with respect to a remaining part (3b) of the substrate (3), the acquired image of the substrate (3) being processed so as to detect the revealed area of interest (3a) on the acquired image and to determine the pattern corresponding to the area of interest (3a) detected on the acquired image.

Abstract: A method for manufacturing cubic diamond nanocrystals (10) comprising the following successive steps: (a) providing crystalline diamond powder where the maximum particle size of the powder is equal or more than 2 um and equal or less than 1 mm; (b) milling said crystalline micron diamond powder using nitrogen jet milling micronization so as to manufacture a fine powder; (c) nanomilling the fine powder of step b) using a planetary tungsten carbide ball mill; (d) acid treating the nanomilled powder of step c); (e) extracting the cubic diamond nanocrystals (10) by centrifugation. Advantageously round-shaped cubic diamond nanocrystals are manufactured.

Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo.

Abstract: The Invention relates to an ex vivo method of diagnosing or predicting a hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the ZFYVE26 gene or protein (spastizin), wherein said mutation is indicative of a hereditary spastic paraplegias (HSP).

Abstract: It relates to the treatment or prevention of a chronic viral infection with a Thymic Stromal Lymphopoietin (TSLP) antagonist thereby avoiding immune evasion and persistence of the virus. It also provides a method of prognosing the evolution of a cervical dysplasia by TSLP expression in a sample of said cervical dysplasia.

Abstract: The invention relates to constitutively active mutants of the prolactin receptor (PRLR), wherein an Ile residue at position 76 or at position 146 of the mature form of said receptor has been substituted by another amino acid residue. The invention also provides methods useful for the diagnosis, prognosis, or treatment of diseases involving the PRLR.

Abstract: The present disclosure describes scFv antibody libraries, antibodies isolated from the libraries, and methods of producing and using the same.

Abstract: The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein or a human immunodeficiency virus (HIV).

Abstract: The invention concerns a novel nucleic sequence and deduced protein sequence family with whole or partial human endogenous retroviral motifs. The invention also concerns the detection and/or the use of said nucleic sequences and said corresponding protein sequences or fragments of said sequences, for diagnostic, prophylactic and therapeutic uses, in particular for neuropathological conditions with autoimmune constituent such as multiple sclerosis. Said purified nucleic acid sequences comprise all or part of a sequence coding for a human endogenous retroviral sequence having at least eny-type retroviral motifs, corresponding to the sequence SEQ ID NO: 1 or to a sequence having a homology level with said sequence SEQ ID NO: 1 not less than 80% of more than 190 nucleotides or not less than 70% on more than 600 nucleotides for env-type domains. The invention further concerns the use of the flanking or adjacent sequence of said sequences and controlled by the latter, as diagnostic reagents.

Abstract: The invention concerns a novel nucleic sequence and deduced protein sequence family with whole or partial human endogenous retroviral motifs. The invention also concerns the detection and/or the use of said nucleic sequences and said corresponding protein sequences or fragments of said sequences, for diagnostic, prophylactic and therapeutic uses, in particular for neuropathological conditions with autoimmune constituent such as multiple sclerosis. Said purified nucleic acid sequences comprise all or part of a sequence coding for a human endogenous retroviral sequence having at least eny-type retroviral motifs, corresponding to the sequence SEQ ID NO: 1 or to a sequence having a homology level with said sequence SEQ ID NO: 1 not less than 80% of more than 190 nucleotides or not less than 70% on more than 600 nucleotides for env-type domains. The invention further concerns the use of the flanking or adjacent sequence of said sequences and controlled by the latter, as diagnostic reagents.

Abstract: Methods for identifying neuroprotective compounds, as well as compositions and methods for treating subjects suffering from neurological diseases or disorders are provided.

Abstract: The invention concerns a novel nucleic sequence and deduced protein sequence family with whole or partial human endogenous retroviral motifs. The invention also concerns the detection and/or the use of said nucleic sequences and said corresponding protein sequences or fragments of said sequences, for diagnostic, prophylactic and therapeutic uses, in particular for neuropathological conditions with autoimmune constituent such as multiple sclerosis. Said purified nucleic acid sequences comprise all or part of a sequence coding for a human endogenous retroviral sequence having at least eny-type retroviral motifs, corresponding to the sequence SEQ ID NO:1 or to a sequence having a homology level with said sequence SEQ ID NO:1 not less than 80% of more than 190 nucleotides or not less than 70% on more than 600 nucleotides for env-type domains. The invention further concerns the use of the flanking or adjacent sequence of said sequences and controlled by the latter, as diagnostic reagents.

Abstract: Group HIV-1 retrovirus strains, particularly the strains known as BCF02, BCF01, BCF06, BCF07, BCF08, BCF11, BCF03, BCF09, BCF12, BCF13 and BCF14, fragments of said retroviruses, and the uses thereof as a diagnostic reagent and as an immunogen, are disclosed.

Abstract: The invention relates to a device generating ultrasonic waves focused in a ocal point. Said generator device comprises a plurality of transducer elements arranged externally on a support means for focusing into a focal point, such as a circular dome, and is characterized in that the transducer elements are divided into at least two groups of transducer elements, of which the resonance frequency differs in such a way that the principal positive ultrasonic waves produced by each group add up together and the positive and negative secondary ultrasonic waves are at least partly cancelled, thus reducing significantly the negative waves. This device can be advantageously used for extracorporeal lithotripsy.